10-Year Research Update Review: Psychiatric Problems in Children With Epilepsy - 12/08/11
, DAVID W. DUNN, M.D., ROCHELLE CAPLAN, M.D.ABSTRACT |
Objective |
To critically review literature published from 1996 to 2007 on psychopathology in children with epilepsy (CWE).
Method |
Using Ovid, we searched Medline and PsychInfo databases for original studies on epidemiology, risk factors, clinical characteristics, treatment, and outcome of psychopathology in CWE, ages 0 to 18 years, using the terms “psychopathology,” “emotional and behavioral problems,” and “mental health problems.” We selectively present the findings of studies that are clinically relevant to mental health professionals.
Results |
Psychopathology occurs in 37% to 77% of CWE, and attention, internalizing, and thought problems may be specific to epilepsy. Cognitive and linguistic deficits, as well as family factors, have moderating effects on psychopathology in CWE. The association of epilepsy-related variables, including antiepileptic drugs, with psychopathology is inconsistent in cognitively normal CWE. Children with symptomatic epilepsy and devastating epilepsy syndromes have high rates of global developmental delay, hyperactivity, and autistic symptoms. The treatment of psychopathology in CWE integrates standard psychiatric practices.
Conclusions |
Epilepsy is a neuropsychiatric disorder characterized by seizures, psychopathology, cognitive, and linguistic problems. Improved early identification of CWE at risk for psychopathology, evidence-based psychiatric treatment, and multidisciplinary management strategies would advance clinical practice in this highly complex field of pediatric neuropsychiatry.
Le texte complet de cet article est disponible en PDF.Key Words : epilepsy, psychopathology, children, cognitive functioning, family factors, antiepileptic drugs
Plan
| Reviewed under and accepted by Michael S. Jellinek, M.D. Disclosure: Dr. Plioplys participates on the speakers’ bureau of Novartis. Dr. Caplan serves as an advisor for GlaxoSmithKline. Dr. Dunn receives research grant support from and participates on the speakers’ bureaus of Eli Lilly, McNeil, Psychogenics, and Novartis. |
Vol 46 - N° 11
P. 1389-1402 - novembre 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
